Amylyx Pharmaceuticals, Inc. AMLX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $27.61M+24.8% | $21.21M-7.3% | $19.86M-6.5% | $27.22M+16.6% | $22.12M-39.6% | ||
| $16.17M+3.1% | $15.39M-10.0% | $16.17M-9.3% | $15.64M-27.7% | $15.68M-72.8% | ||
| $43.78M+15.8% | $36.61M-8.5% | $36.03M-52.6% | $42.86M-43.1% | $37.8M-82.1% | ||
| -$43.78M-15.8% | -$36.61M+10.0% | -$36.03M+52.4% | -$42.86M+43.8% | -$37.8M+69.0% | ||
| $2.57M+15.2% | $3.29M+42.1% | $1.82M-41.2% | $1.96M-51.8% | $2.23M-48.4% | ||
| $2.5M+31.6% | $3.65M+47.7% | $1.64M-44.5% | $1.41M-60.6% | $1.9M-47.0% | ||
| —— | -$32.95M+13.7% | -$34.39M+52.7% | -$41.44M+43.0% | -$35.91M+69.7% | ||
| —— | $46K+107% | $0— | $0— | $0-100% | ||
| -$41.28M-15.0% | -$33M+12.1% | -$34.39M+52.7% | -$41.44M+43.0% | -$35.91M+69.8% | ||
| -$0.37+11.9% | -$0.28+48.1% | -$0.37+65.4% | -$0.46+57.0% | -$0.42+76.0% | ||
| -$0.37+11.9% | -$0.28+48.1% | -$0.37+65.4% | -$0.46+57.0% | -$0.42+76.0% | ||
| 110.6M+29.0% | 94.6M+38.8% | 93.3M+37.1% | 89.1M+31.0% | 85.7M+26.3% | ||
| 110.6M+29.0% | 94.6M+38.8% | 93.3M+37.1% | 89.1M+31.0% | 85.7M+26.3% | ||
| -$75K+77.6% | —— | -$180K-27.7% | -$546K-13.0% | -$335K+55.2% | ||
| -$43.78M-15.8% | -$36.61M+10.0% | -$36.03M+52.4% | -$42.86M+43.8% | -$37.8M+69.0% | ||
| -$43.68M-16.0% | -$36.5M+9.9% | -$35.91M+52.4% | -$42.72M+43.9% | -$37.65M+69.1% | ||
| -$43.68M-16.0% | -$36.5M+9.9% | -$35.91M+52.4% | -$42.72M+43.9% | -$37.65M+69.1% | ||
| -$43.78M-15.8% | -$36.61M+10.0% | -$36.03M+52.4% | -$42.86M+43.8% | -$37.8M+69.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 100.0% and operating margin is -47349.8%, with a -45096.2% net margin.
- Where does Amylyx Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.